Effect of ruxolitinib on the oral mucosa in steroid-refractory graft-versus-host disease: a prospective observational exploratory study.

ABSTRACT:

Objectives

To assess whether Steroid-Refractory chronic Graft-versus-Host Disease (SR-cGvHD) patients with oral involvement benefit from ruxolitinib regarding their clinical symptoms and oral lesions.

Materials and methods

A prospective real-life observational longitudinal patient study was conducted in patients with SR-cGVHD and oral involvement who were treated with ruxolitinib. The effects of ruxolitinib on oral lesions and symptoms were assessed 12 weeks after the start of treatment with ruxolitinib based on the complete response, partial response, and overall response rate. Additionally, oral mucosal clinical characteristics and symptoms were assessed using validated outcome scales 4 and 12 weeks after treatment.

Results

A total of 17 patients was included. Overa

SUBMITTER: Bellido M 

PROVIDER: S-EPMC12589367 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature